ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SNG Synairgen Plc

4.675
0.00 (0.00%)
Last Updated: 08:00:27
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.675 4.36 4.99 - 38,838 08:00:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.41M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.68p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.41 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 2376 to 2394 of 99175 messages
Chat Pages: Latest  103  102  101  100  99  98  97  96  95  94  93  92  Older
DateSubjectAuthorDiscuss
03/4/2020
22:33
Dave - I agree completely with you!
finster007
03/4/2020
22:06
I expect a bounce next week now the tax year end profit take is over!
dave444
03/4/2020
22:04
If Blackrock continue to reduce Link’s holding we could see further drop next week while we continue to pick up new holders.
Depends how much of Woodford’s holding is left, I guess.

wetdream
03/4/2020
21:51
It looks like the city boys have been loading for their clients for what's coming or that is what the gent on the lse board who worked as an institutional sales/trader in the 90s thinks.
likya123
03/4/2020
21:43
Likya. What is that to do with here is it a cross stock ramp.
dealer55
03/4/2020
21:32
Definitely
the patient investor
03/4/2020
21:04
It does look like we have had to absorb a big volume seller which looks like the RNS amounts and another 3 million or so if in fact he has sold out fully. Those late trades are pretty big so someone buying. Expected 70p this week at close shame, maybe next week will be better. I wonder what next news will be update on recent USA appearance or manufacturing agreements? Update on patient numbers? I think we will get some sort of news next week.
crookie3634
03/4/2020
20:53
From JCEP lse board...

Brokers are so dodgy on AIM. Late and large delayed buy orders on the 2nd ! Hunch tells me they are legging into their big clients. I get it...you have to pay the ferryman. 
This tells me one is being lined up here. I was an institutional sales/trader in the 90s...the patterns are increasingly clear. 
I’m long the stock and remain bullish over next 6 weeks.

likya123
03/4/2020
20:37
I am fuming to be honest .. they talked about medical trial just to deflect away from the mega balls up on testing . One jorno asked why Germany and south Korea are doing great work i.e. have less deaths ? the replies were utter trash to be honest . Test and test again should be the mantra else the virus is going to spread and spread resulting in more deaths dont they understand ..
pal44
03/4/2020
20:34
Patient Investor, thought u was maxed out elsewhere, or did u sell some of ur golden shares to join the gang here
yet another final
03/4/2020
20:28
Haha likya, you have a habit of repeating my posts - keep it up, it’s always good to see it more than once ;)
makendon
03/4/2020
20:12
Nobby what should I drink to forget the losses?
adman50
03/4/2020
19:46
tx Lykia, great find and just published today

I agree, the verb chosen is very promising

i made it clickable

the patient investor
03/4/2020
19:42
"The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed"

"Confirm" is an interesting word choice and almost as if they know it works but just getting confirmation. I like this choice of word, it fills me with yet more confidence about what's about to happen here.


Urgent public health studies!



A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

Study type:
Interventional

Summary:
The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.

Chief Investigator:
Professor Tom Wilkinson University Hospital Southampton NHS Foundation Trust

Sponsor:
Synairgen Research Limited

Funder:
Synairgen Research Limited

IRAS Number:
281317

CPMS ID:
45382

likya123
03/4/2020
19:22
Andrew Pierce has it and is off air.
bmnsa
03/4/2020
19:21
Only those with the lergy can apply(covid19)
bmnsa
03/4/2020
18:38
3fiona

I did listen to it too, impressive accurate summary! thx

the patient investor
03/4/2020
18:35
From BBC Prof Van Tam: Search for treatments ongoingProfessor Jonathan Van Tam says to find the most effective treatments you need to find out "the right dosage to use, the right patient to give it to and the right time to give it".The deputy chief medical officer says it is "complicated stuff and the only way to unpick signals and get it right is clinical trials".He confirms there are three trials already running, and the recruitment rate has been "astonishing".The trials are focusing on existing drugs that may be used for something else, but they are going to move on to looking at new medicines in development.Prof van Tam cannot give a date for when this will happen, saying it is going to be a "few months", "but it will all depend how quickly patients are recruited into the trials".He adds: "The faster we go... the clearer and more emphatic signals we will get about what works and who it works for."
3fiona
03/4/2020
17:59
Just found this updated or released today :)

Titled: Urgent public health studies!



A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

Study type:
Interventional

Summary:
The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.

Chief Investigator:
Professor Tom Wilkinson University Hospital Southampton NHS Foundation Trust

Sponsor:
Synairgen Research Limited

Funder:
Synairgen Research Limited

IRAS Number:
281317

CPMS ID:
45382

makendon
Chat Pages: Latest  103  102  101  100  99  98  97  96  95  94  93  92  Older

Your Recent History

Delayed Upgrade Clock